Sign in Subscribe
Diabetes mellitus

Insulin Detemir Shows Promise in Diabetes Treatment

Strategic Insights

— 1 min read

Diabetes Week editors reported on a recent study, presented at the 64th annual meeting of the American Diabetes Association in Orlando, Florida, where insulin detemir demonstrated significant improvements in A1C levels, fasting blood-glucose variability, and reduced risk of nighttime hypoglycemia and weight gain compared to NPH insulin. The study highlights the challenges of predictability in conventional insulin therapies, leading to increased risk of side effects. Insulin detemir's unique chemical structure and slow absorption from the injection site result in consistent blood-glucose levels, providing a more stable treatment option.

Key Takeaways:

  • Insulin detemir achieved similar improvement in A1C levels as NPH insulin, but with significantly lower day-to-day variability in fasting blood-glucose levels.
  • The study demonstrated a reduced risk of nighttime hypoglycemia and weight gain compared to NPH insulin.
  • The unique chemical structure of insulin detemir leads to slow and stable absorption from the injection site, resulting in consistent blood-glucose levels.
  • Insulin detemir has shown benefits over currently available insulin therapies in previous studies.
  • Clinicians struggle to help patients achieve optimal control without life-altering side effects, leading to interest in insulin detemir as a potential solution.
  • Mari-Anne Gall, MD, and Peter Aurup, MD, from Novo Nordisk Pharmaceuticals, Inc., expressed enthusiasm for the potential benefits of insulin detemir in diabetes treatment.

Statistics:

  • 14 research papers examining the role of insulin detemir in the treatment of diabetes were presented at the 64th annual meeting of the American Diabetes Association.
  • 64th annual meeting of the American Diabetes Association was held in Orlando, Florida.
  • Insulin detemir has demonstrated a significant reduction in nighttime hypoglycemia risk and weight gain compared to NPH insulin.

Sources:

  • NewsRx.com & NewsRx.net, 2004 JUL 5
  • Diabetes Week, Copyright 2004, via NewsRx.com & NewsRx.net

Read more